Yves Humblet
Overview
Explore the profile of Yves Humblet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
7250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, et al.
Cell
. 2018 Oct;
175(3):751-765.e16.
PMID: 30318143
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in a longitudinal dataset of colorectal cancer. Through multiplexed analyses, we showed that clonal evolution patterns during...
2.
Corcoran R, Andre T, Atreya C, Schellens J, Yoshino T, Bendell J, et al.
Cancer Discov
. 2018 Feb;
8(4):428-443.
PMID: 29431699
Although BRAF inhibitor monotherapy yields response rates >50% in -mutant melanoma, only approximately 5% of patients with colorectal cancer respond. Preclinical studies suggest that the lack of efficacy in colorectal...
3.
Mlecnik B, Van den Eynde M, Bindea G, Church S, Vasaturo A, Fredriksen T, et al.
J Natl Cancer Inst
. 2017 Sep;
110(1).
PMID: 28922789
Background: This study assesses how the metastatic immune landscape is impacting the response to treatment and the outcome of colorectal cancer (CRC) patients. Methods: Complete curative resection of metastases (n ...
4.
Hoton D, Humblet Y, Libbrecht L
Histopathology
. 2017 Sep;
72(4):707-710.
PMID: 28888040
No abstract available.
5.
Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, et al.
ESMO Open
. 2017 Aug;
1(6):e000111.
PMID: 28848658
Objective: To identify imaging markers predicting clinical outcomes to regorafenib in metastatic colorectal carcinoma (mCRC). Methods: The RadioCORRECT study is a post hoc analysis of a cohort of patients with...
6.
Sacre A, Lanthier N, Dano H, Aydin S, Leggenhager D, Weber A, et al.
Liver Int
. 2016 Aug;
36(11):1590-1594.
PMID: 27500989
Background: Regorafenib is the first small-molecule multikinase inhibitor which showed survival benefits in pretreated metastatic colorectal cancer (mCRC) patients. Besides classical adverse events of this drug class, hepatotoxicity has been...
7.
De Greve J, Meerbeeck J, Vansteenkiste J, Decoster L, Meert A, Vuylsteke P, et al.
PLoS One
. 2016 Apr;
11(3):e0147599.
PMID: 27032107
Introduction: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data...
8.
Smajda S, Danse E, Mertens de Wilmars M, Humblet Y, Kartheuser A, Jouret-Mourin A
Acta Gastroenterol Belg
. 2015 Dec;
78(4):431-5.
PMID: 26712056
The authors report the case of a 29-year-old woman with partially calcified stage cT4N2M0 mucoid adenocarcinoma of the mid-rectum. Concomitant neoadjuvant chemoradiotherapy was administered. Preoperative CT scan and MRI demonstrated...
9.
Van Cutsem E, Joulain F, Hoff P, Mitchell E, Ruff P, Lakomy R, et al.
Target Oncol
. 2015 Dec;
11(3):383-400.
PMID: 26706237
The aim of this post hoc analysis of the VELOUR study (ClinicalTrials.gov NCT00561470) was to investigate the treatment effect of adding aflibercept to second-line infusional 5-fluorouracil (5-FU), leucovorin and irinotecan...
10.
Tabernero J, Lenz H, Siena S, Sobrero A, Falcone A, Ychou M, et al.
Lancet Oncol
. 2015 Jul;
16(8):937-48.
PMID: 26184520
Background: Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the genotype of the tissue obtained at the time of diagnosis...